Volume 10, Issue 6, June – 2025 International Journal of Innovative Science and Research Technology
ISSN No:-2456-2165 https://doi.org/10.38124/ijisrt/25jun817

Unveiling ; Osteopontin Role in Chronic Liver Disease: Insight and Implication

Muhammed Fadhel Pandalingal[1]; Awad El-Hakeem[2]

[1]Department of Medicine, Faculty of Medicine, Tbilisi State Medical University, Georgia
[2]Department of Medicine, Faculty of Medicine, Tbilisi State Medical University, Georgia

Publication Date: 2025/06/17

Abstract: Osteopontin (OPN) is a prominent integrin glycoprotein that plays a considerable role in the progression of chronic hepatic disorders. OPN has more recognized functions, including liver inflammation, fibrosis, and tumours, having once been purely renowned in bone metabolism and cellular adhesion processes. It is convincing that OPN is a good biomarker candidate to assist in the accurate diagnosis of liver diseases, as its increased concentrations coincide with liver damage, fibrosis, and cancer. Chronic liver disease conditions such as alcoholic liver disease and NAFLD depict OPN-driven stellate cells, immune cells, and lipids entering the liver, causing damage and fibrogenesis. In hepatocellular carcinoma, OPN facilitates progression and metastasis through tumour colonization, blood vessel formation, and immune suppression. This supports OPN's potential as a biomarker to be further investigated in liver damage assessment. This research explains the molecular basis of OPN's role in liver inflammation and fibrosis, identifies its regulatory pathways, and explores its clinical relevance to liver cancer. The work extends to OPN's complex functions and utility as a potential therapeutic drug target using in vivo and in vitro models, alongside advanced molecular and histological techniques. Assuming insights into OPN's regulation and pathological consequences are effective, new therapeutic strategies, including OPN inhibitors or neutralizing antibodies, could be envisaged. These strategies could lead to better control of chronic liver disease and its associated cancers.

Keywords: *Osteopontin (OPN), Chronic Liver Disease, Liver Fibrosis, Hepatocellular Carcinoma, Biomarker for Liver Damage.*

How to Cite: Muhammed Fadhel Pandalingal; Awad El-Hakeem (2025) Unveiling ; Osteopontin Role in Chronic Liver Disease: Insight and Implication. *International Journal of Innovative Science and Research Technology*, 10(6), 869-872. https://doi.org/10.38124/ijisrt/25jun817

I. INTRODUCTION

Osteopontin has been recognized as a glycoprotein that is significantly engaged in such processes as bone resorption, bone formation and immune reactions. The term 'osteopontin' comes from its first recognition as a bone-associated protein , in which ribonucleic acid (RNA) translation to protein included also the provision of adhesion to the cells, considering the Greek word "osteon" which means bone and Latin word "pontin," meaning bridges [(1)]. Moreover, OPN's structure contains a high number of acidic amino acids which interact with integrins and CD44 to enhance cellular attachment and migration, and promotes OPN's SDM to wonder both in the inflammatory and the fibrotic cells of the liver, where it is significant as well as within the cancerous lesions, indicating its multiplicity of functionality within normal physiology and diseased states [(2)].

Other than metabolism of the bones, OPN also has important roles in cell signaling, tissue repair and immune modulation. OPN for instance has been noted to aid in controlling responses towards inflammation and the activity of hepatic stellate cells that are key in fibrosis within the liver [(3)]. In addition, OPN appears to affect the mobility, and activation of the immune cells, thus contributing to the liver functions during damaging situations or infection [(2)]. It is over expressed in a number of liver ailments providing evidence that it can be a useful biomarker to assess how severe a liver condition is or its progression effect [(1)]

The presence of OPN has been noted in chronic liver diseases as a result of liver damage, inflammation, and fibrosis. Research has shown that OPN is frequent in high amounts in alcoholic liver disease (ALD) and non-alcoholic fatty liver disease (NAFLD), and that the two are positively related along the level of inflammation and liver scarring [(4)] [(5)]. OPN however has other functions apart from those that include steatosis and recruiting inflammatory cells to target organs [(3)]. This infers that OPN is useful in determining whether or not there are changes in the liver but it also causes changes in the organs in cases of chronic liver diseases.

It's captivating to note the link between OPN and hepatic steatosis particularly as OPN has been associated with the etiology and the progression of both alcoholic and non alcoholic fatty liver diseases. OPN levels are higher in the cirrhotic patients and correlate with the degree of steatosis and inflammation, suggesting a role in alcohol-induced liver injury [(6)] [(5)]. Also, in NAFLD, OPN has been noted to promote the accumulation of lipids in hepatocytes which is associated

ISSN No:-2456-2165 https://doi.org/10.38124/ijisrt/25jun817

with the transition from simple steatosis to non-alcoholic fatty liver disease i.e. steatohepatitis (NASH) [7]. The relationship between OPN and lipid metabolic processes makes OPN an interesting target for the treatment of fatty liver diseases.

In terms of liver cancer, and in particular hepatocellular carcinoma (HCC), OPN has been identified as one of the crucial determinants of tumour growth as well as metastasis. In HCC patients, elevation of OPN has been found to correlate with poor disease outcome, and its over expression is associated with the development of some molecular pathways involved in tumour formation, for example those involved in the regulation of cell growth as well as apoptosis [1] [2]. OPN's role in dealing with the tumour microenvironment, neovascularization and immune escape also makes sense for it in liver cancer [1]. This makes not only makes OPN a serum marker of liver cancer but also a target for therapeutic intervention.

II. OBJECTIVES

When studying OPN in chronic liver disease, one sphere of interest is the role that OPN plays in liver pathology, its mechanisms of regulation and the possibility of its targeting for therapy. More specifically, OPN is believed to facilitate liver inflammation and fibrosis, essential features of chronic liver diseases from the point of view of some researchers [1] [2]. Hence, by explaining the OPN activity, the research is intended to increase understanding of the mechanisms contributing to the development of liver diseases and pinpoint the opportunities for therapeutic strategies.

Furthermore, it is also important to explore the regulatory mechanisms responsible for OPN expression specifically in the liver during disease states. Similarly, this specific activity may explain the transcriptional and post translational events which contributes to the OPN levels during liver disease progression [3] [7]. This knowledge is crucial in the design of liver disease therapies targeting OPN that are likely to reduce the pathological consequences of OPN signaling.

The investigation seeks to also determine how OPN is related to hepatocellular carcinoma (HCC). The specific aims of the study include the exploration of the association between HCC development and OPN expression with a view to uncovering possible biomarkers that would allow for early diagnosis and HCC prognosis, and treatment options that would be amenable to intervention [1] [2]. This is important given the rising trends for liver cancers and the need for effective management approaches.

In addition, the study will assess the treatment potential chronic liver diseases targeting OPN. This encompasses studying the effect of OPN blocking monoclonal antibodies or OPN antagonists as therapies to limit liver inflammation and fibrosis [8] [9]. The findings of this study could therefore lead to the identification of appropriate treatment methods for chronic liver diseases and contribute to positive health outcomes of patients.

III. METHODOLOGY

To study OPN in association with chronic liver disease, different experimental models are utilized, in particular, in vivo and in vitro models. In vivo models frequently employ genetically modified mice or use animal models of liver damage due to The in vitro studies often use primary cultures of hepatocytes or hepatic stellate cell lines to study responses of OPN and regulation of its mechanisms [3][7]. high-fat or alcohol feeding meant to replicate the pathophysiology of liver diseases in humans [9] [10].

Serum OPN and its liver tissue levels are measured by quantitative PCR and western blot, as well as ELISA assays. All of these methods allow one to assess the level of OPN expression and its association with the severity of diseases [4][1]. To determine the presence of OPN in liver tissues, immunohistochemistry assays are also performed, which help in understanding the function of OPN in particular cells [3].

In experimental models, liver inflammation and liver fibrosis can be measured histologically by measuring liver tissue remodelling and collagen deposition through the use of hematoxylin and eosin (H&E) staining and Masson's trichrome staining [9] [11]. Furthermore, liver function test assays are conducted to estimate the levels of markers of liver damage, whereas ultrasound or MRI may be employed to examine the liver structure and presence of fibrosis [4][11].

Flow cytometry is used to assess the involvement of OPN in immune cells as well as in liver injury by evaluating immune cell populations while cytokine profiling determines the levels of inflammatory mediators [8][9]. This perspective gives deeper insight into the role of OPN in the modulation of the immune system in the setting of liver disease.

Statistical analysis is one of the key tools that facilitates interpretation of results from these studies. Frequently used techniques are regression modelling for the analysis of relationship between OPN measurements and selected clinical parameters, survival analysis for determination of prognostic value, and means comparing group means using anova and t tests for the purpose of evaluating significance of findings [4] [11]. With these statistical measures, firm conclusions may be made from the findings of the experiments.

IV. RESULTS

The first in a series of studies looking at OPN and chronic liver disease show a complex relationship between OPN and liver diseases such as liver fibrosis, steatosis, and HCC. It has been found that there is an inverse correlation between OPN and chronic liver disease, wherein high levels of OPN are present with high liver fibrosis and inflammation [9] [5], thus OPN can also be termed as being potentially druggable. Furthermore, OPN's involvement in the regulation of lipid content in liver cells suggests its involvement in both alcoholic distinct and non alcoholic distinct liver diseases as well [1] [7].

ISSN No:-2456-2165 https://doi.org/10.38124/ijisrt/25jun817

In terms of liver cancer, HCC is characterized by reduced life expectancy and the level of OPN gives an indication of how cancer is progressing, thus promising for HCC prognosis [(1)(2)]. This association both emphasizes the external validity of the initial correlation and the need for future studies examining the relevance of OPN in cancer biology and liver malignancy therapeutics.

The last paragraph pointed towards the underlying effect of OPN in chronic liver disease and potential treatment targeting of OPN via neutralizing antibodies and developing effective OPN inhibitors as treatment options in order to decrease liver inflammation and fibrotic changes in the liver [(8) (9)]. These advances could result in enhanced therapies for patients with chronic liver conditions and enhance the quality of living of the patients as well.

Liver disease is an insult to the body in one or another form. In this timeline, there are advancements that are made by professionals in order to reverse the hands of time and help those suffering from chronic liver disease. For this purpose, the findings from the study that highlight the correlation between OPN levels and clinical markers of liver diseases provide tremendous value, all the while also showcasing how OPN has the potential to act as a biomarker for liver diseases.

With the help of analyzing the role of OPN in chronic liver disease, OPN opens the gates for new chronic liver disease treatments which treat damaged liver tissues along with reversing liver inflammation and reducing cancer cell growth as well.

V. DISCUSSION

Recent research has stressed the important job of OPN in liver fibrosis and inflammation with a special emphasis on chronic liver diseases. It is known that OPN supports recruitment of hepatic stellate cells which actively promotes fibrogenesis and it is also reported that the level increases proportionally with liver damage and fibrosis [(3)(5)]. Looking at this, it is reasonable to assume that OPN could be targeted in order to treat liver fibrosis since high levels of OPN are something that could be aimed at reducing in order to help return the liver to normal functioning [(8)(9)].

In fact, findings that are now being reported do confirm some earlier facts but there are some elements which seem to contradict previous claims in regard to role of OPN in chronic liver disease. Although a considerable amount of literature is available which states the importance of OPN in the process of liver inflammation and or liver fibrosis, a number of controversies exist regarding the mechanisms and pathways in which OPN operates [(4)-(5)]. This shows that there is so much that is not understood about OPN in relation to liver disease and more research needs to be conducted so as to be able to define the roles of OPN.

It would be good to look into how OPN mediates its function in HCC molecularly. OPN has been detoxified to bear the effects of fostering tumour development and its distance spread through processes such as the ones controlling angiogenesis and immune response management. For instance, we would be implementing a strategy to decipher these pathways so that we can establish a mechanism to effectively counter the adverse impacts of OPN in liver malignancies and most effectively combat HCC.

The modulation of OPN appears to be a promising therapeutic avenue to explore in the treatment of liver diseases. The targeting of OPN by OPN inhibition or blocking may be new strategies to enhance suppression of liver inflammation and fibrosis thereby improving liver diseases [(8)(9)]. In addition, the concentration of OPN could be employed in tracking the course of the disease and the effect obtained from therapy thus improving the clinical applicability of OPN [(4)(1)].

However, of concern are the limitations of the study including, among other factors, bias in sample selection, the necessity of studying the problem in a longitudinal manner, and the challenge of extrapolating results found in animal studies to studies in humans. The researchers were aware that these considerations might limit the extent to which the findings could be generalized.

VI. CONCLUSION

The literature reviewed indicates that osteopontin (OPN) is a significant factor in the development of chronic liver diseases, including fibrosis, steatosis, and even hepatocellular carcinoma (HCC). Studies have noted that patients experiencing liver inflammatory disease, liver fibrosis as well as dyslipidemia caused by alcoholic liver disease (ALD) and non-alcoholic fatty liver disease (NAFLD) had a noticeable increase in OPN levels [(5, 6, 7)]. In particular, OPN further fuels the activation of hepatic stellate cells and matrix deposition which are important factors in liver fibrosis development [(3, 5)] Eng.

In the case of liver cancer, OPN plays a crucial role in tumour growth, angiogenesis, distant metastasis, immune evasion and tumour microenvironmental regulation, which eventually contributes to poor prognosis or treatment response, hence a useful diagnostic and therapeutic marker [(1, 2)]. Inhibition of OPN receptor on key immune cells and blocking the silencing of OPN by the overexpression of IL-6 neutralizing antibodies demonstrate suitable experimental conditions to treat intralesional liver inflammation, fibrosis or the progression of steatosis to steatohepatitis [(8, 9)]. OPN-/- mouse further demonstrates the efficacy of targeted treatment of steatosis and steatosis-mediated further fibrosis by OPN deficiency [(10, 11)].

However, while these achievements have been notable, there still exist questions as to why OPN behaves the way it does, the specific motifs or structures associated with its downstream pathways etc. Filling in these questions is crucial in refining clinical therapeutic approaches targeting OPN.

ISSN No:-2456-2165 https://doi.org/10.38124/ijisrt/25jun817

REFERENCES

[1]. Song, Z., Chen, W., Athavale, D., Ge, X., Désert, R., Das, S., … & Nieto, N. (2021). Osteopontin takes center stage in chronic liver disease. Hepatology, 73(4), 1594-1608. https://doi.org/10.1002/hep.31582

[2]. Desert, R., Ge, X., Song, Z., Han, H., Lantvit, D., Chen, W., Das, S., Athavale, D., Abraham-Enachescu, I., Blajszczak, C., Chen, Y., Musso, O., Guzman, G., Hoshida, Y., & Nieto, N. (2022). Role of Hepatocyte-Derived Osteopontin in Liver Carcinogenesis. *Hepatology communications*, *6*(4), 692–709. https://doi.org/10.1002/hep4.1845

[3]. Tan, Y., Zhao, L., Yang, Y. G., & Liu, W. (2022). The Role of Osteopontin in Tumor Progression Through Tumor-Associated Macrophages. *Frontiers in oncology*, *12*, 953283. https://doi.org/10.3389/fonc.2022.953283

[4]. Yi Liang, T. (2023). Osteoporosis and Chronic Liver Disease. In *Osteoporosis, Osteoarthritis and Rheumatoid Arthritis: An Agonizing Skeletal Triad* (pp. 1-16). Bentham Science Publishers.https://doi.org/10.4236/ojgas.2018.812045

[5]. Vachliotis, I. D., Anastasilakis, A. D., Rafailidis, V., & Polyzos, S. A. (2024). Osteokines in Nonalcoholic Fatty Liver Disease. *Current Obesity Reports*, *13*(4), 703-723.https://doi.org/10.1002/hep.23998

[6]. Drapkina, O. M., Elkina, A. Y., Sheptulina, A. F., & Kiselev, A. R. (2023). Non-alcoholic fatty liver disease and bone tissue metabolism: current findings and future perspectives. *International Journal of Molecular Sciences*, *24*(9), 8445.

[7]. Vachliotis, I. D., Anastasilakis, A. D., Rafailidis, V., & Polyzos, S. A. (2024). Osteokines in Nonalcoholic Fatty Liver Disease. *Current Obesity Reports*, *13*(4), 703-723.

[8]. Bianchi, E., Rontauroli, S., Tavernari, L., Mirabile, M., Pedrazzi, F., Genovese, E., ... & Manfredini, R. (2023). Inhibition of ERK1/2 signaling prevents bone marrow fibrosis by reducing osteopontin plasma levels in a myelofibrosis mouse model. *Leukemia*, *37*(5), 1068-1079.

[9]. Honda, M., Kimura, C., Uede, T., & Kawa, S. (2020). Neutralizing antibody against osteopontin attenuates non-alcoholic steatohepatitis in mice. Journal of Cell Communication and Signaling, 14(2), 223-232. https://doi.org/10.1007/s12079-020-00554-7

[10]. Soysouvanh, F., Rousseau, D., Bonnafous, S., Bourinet, M., Strazzulla, A., Patouraux, S., ... & Gual, P. (2023). Osteopontin-driven T-cell accumulation and function in adipose tissue and liver promoted insulin resistance and MAFLD. *Obesity*, *31*(10), 2568-2582.

[11]. Schulien, I., Hockenjos, B., Schmitt-Graeff, A., Perdekamp, M., Follo, M., Thimme, R., … & Hasselblatt, P. (2019). The transcription factor c-jun/ap-1 promotes liver fibrosis during non-alcoholic steatohepatitis by regulating osteopontin expression. Cell Death and Differentiation, 26(9), 1688-1699. https://doi.org/10.1038/s41418-018-0239-8